Johnson & Johnson said worldwide sales for Q2 of fiscal 2025 were $23.7 billion, an increase of 5.8%, and sales for the 6 months were $45.6 billion, an increase of 4.1%. The company said the negative impact of the Stelara sales decline on operational sales for the 6 months was approximately 5.9%.

1. 01

   Johnson & Johnson said worldwide sales for Q2 of fiscal 2025 were $23.7 billion, an increase of 5.8%, and sales for the 6 months were $45.6 billion, an increase of 4.1%. The company said the negative impact of the Stelara sales decline on operational sales for the 6 months was approximately 5.9%.

2. 02

   Johnson & Johnson said Innovative Medicine sales for Q2 were $15.2 billion, an increase of 4.9%, and MedTech sales were $8.5 billion, an increase of 7.3%. The company said the impact of the Stelara sales decline on Innovative Medicine operational sales was approximately 11.7%.

3. 03

   Johnson & Johnson said consolidated earnings before provision for taxes on income for the 6 months of fiscal 2025 were $20.1 billion, representing 44.1% of sales, compared with $9.5 billion, representing 21.6% of sales, for the same period a year ago. The company said the 6 months of 2025 included a reversal of approximately $7.0 billion of the talc reserve, and the 6 months of 2024 included charges for talc matters of approximately $3.0 billion.

4. 04

   Johnson & Johnson said as of June 29, 2025, cash, cash equivalents and current marketable securities were approximately $18.9 billion, and notes and long-term debt were approximately $50.8 billion, resulting in net debt of $31.9 billion. The company said it used the net proceeds from senior unsecured notes issued in Q1 for the Intra-Cellular acquisition, which closed on April 2, 2025, for approximately $14.5 billion.

Key figures

Quarter ended June 29, 2025

Revenue

$23.7B

Net income

$5.5B

EPS

$2.29

Gross profit

$16.1B

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.